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Statement of findings
Mesenchymal precursor cells found in the blood (BMPCs) of normal persons adhere to
plastic and glass and proliferate logarithmically in DMEM–20% fetal calf serum (FCS)
without growth factors. They form cells with fibroblast-like and stromal morphology, which is
not affected by eliminating CD34, CD3, or CD14 cells. Osteogenic supplements
(dexamethasone, ascorbic acid, and b-glycerophosphate) added to the culture inhibited
fibroblast formation, and BMPCs assumed the cuboidal shape of osteoblasts. After 5 days in
supplemented medium, the elutriated cells displayed alkaline phosphatase (AP), and the
addition of bone morphogenetic protein (BMP)2 (1ng) doubled AP production (P<0.04).
Two weeks later, 30% of the cells were very large and reacted with anti-osteocalcin
antibody. The same cultures also contained sudanophlic adipocytes and multinucleated
giant cells that stained for tartrate-resistant acid phosphatase (TRAP) and vitronectin
receptors. Cultured BMPCs immunostain with antibodies to vimentin, type I collagen, and
BMP receptors, heterodimeric structures expressed on mesenchymal lineage cells. In
addition, BMPCs stain with anti-CD105 (endoglin), a putative marker for bone-marrow
mesenchymal stem cells (MSCs).
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AP = alkaline phosphatase; BMP = bone morphogenetic protein; BMPCs = mesenchymal precursor cells found in the blood; BMPRs = bone mor-
phogenetic protein receptors; BSA = bovine serum albumin; CSF = colony stimulating factor; DMEM = Dulbecco’s modified Eagle’s medium;
EDTA = ethylenediaminetetraacetic acid; FACS = fluorescence-activated cell sorter; FCS = fetal calf serum; GA3PD = glyceraldehyde-3-phos-
phate dehydrogenase; HSCs = hematopoietic stem cells; MACS = magnetic antibody-coated-bead separation; MSCs = mesenchymal stem cells;
OCs = osteoclasts; OD = optical density; PBS = phosphate-buffered saline; PBSF = pre-B-cell-growth-stimulating factor; RA = rheumatoid arthri-
tis; RPMI = RPMI-1640 medium; RT-PCR = reverse transcriptase polymerase chain reaction; SDF-1 = stromal-cell-derived factor 1; TGF = trans-
forming growth factor; TRAP = tartrate-resistant acid phosphatase.
Introduction:  Adult human bone marrow contains a minority
population of MSCs that contribute to the regeneration of tissues
such as bone, cartilage, muscle, ligaments, tendons, fat, and
stroma. Evidence that these MSCs are pluripotent, rather than
being a mixture of committed progenitor cells each with a
restricted potential, includes their rapid proliferation in culture, a
characteristic morphology, the presence of typical marker
proteins, and their consistent differentiation into various
mesenchymal lineages. These attributes are maintained through
multiple passages and are identifiable in individual stem cells.
Aims: Since stem cells are present in both the bone marrow
and other tissues, we thought it possible that cells with a
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Introduction
Bone marrow is a complex tissue containing hematopoietic
cell progenitors and their progeny and a connective-tissue
network of mesenchymally derived cells known as stroma.
Marrow stroma includes a subpopulation of undifferenti-
ated cells that are capable of becoming one of a number of
phenotypes, including chondrocytes, osteoblasts,
adipocytes, fibroblasts, possibly muscle cells, and the retic-
ular cells that support hematopoietic cell differentiation
[1,2]. Extensive experimentation has defined conditions for
the isolation, propagation, and differentiation in vitro and in
vivo of the stromal cells referred to as MSCs. They are a
population of firmly adherent cells with a high proliferative
capacity and potential for self-renewal. Their developmental
potential is retained even after repeated subcultivation in
vitro, supporting their designation as stem cells [3].
Identification of MSCs in situ has been difficult, partly
because they have few unique products or molecular
markers. A series of monoclonal antibodies (SH antibodies)
purportedly specific reagents have been used to isolate
MSCs from a population of bone-marrow cells [1,3]. The
one used most often (SH-2) was recently shown to react
with endoglin (CD105), a member of the transforming
growth factor (TGF)-b receptor family usually found on the
endothelium of postcapillary venules [4]. Two other
reagents may be more specific. One consists of a group of
antibodies to BMP receptors (BMPRs) present on
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similar appearance and pluripotent mesenchymal potential
would be present in the blood. We applied techniques used
successfully with marrow MSCs to identify similar cells in
elutriation fractions of normal human blood.
Methods: BMPCs were elutriated by diluting the buffy coats
from 500ml of anticoagulant-treated, platelet-depleted blood
1:4 in RPMI-1640 medium (RPMI) and layering 25-ml portions
over 20ml of Lymphoprep™. These samples were centrifuged
at 2000rpm for 20 min. The leukocyte-rich interface cells were
collected, made up to 20ml in RPMI, and separated by density-
gradient centrifugation. The interface cells, now depleted of red
blood cells, were collected, resuspended in 50ml of sterile
RMPI and 5% heat-inactivated FCS, and introduced into the
sample line of the flow system of a Beckman JE-50 cell
elutriator charged with elutriation buffer. The chamber was
centrifuged at 25000rpm at 10°C and the flow rate adjusted
to 12ml/min. After about 150ml had been collected, the flow
rate was increased by 1ml/min. Fractions nos. 1–6 (flow rates
of 12–16ml/min) contained most of the lymphocytes.
Monocytes usually appeared in fractions 6 or 7 (as determined
by flow cytometric analysis in a fluorescence-activated cell
sorter (FACS). BMPCs were concentrated in fractions 7 and 8,
along with monocytes and lymphocytes. Elutriation fractions
with more than 50% and less than 75% monocytes were
collected and concentrated by centrifugation at 1200rpm for
5min, and the cell pellets were combined, reconstituted in
DMEM plus 20% sterile heat-inactivated FCS, counted,
washed in medium, repelleted, and then resuspended in
DMEM to 5×106/ml and dispensed into either tissue-culture
plastic slides or glass chamber slides. Cells thus obtained
were observed in time-lapse cinematography, assayed for
proliferation, and examined immunohistologically and
histochemically, and their ability to become fibroblasts,
osteoclasts, osteoblasts, and adipocytes was documented.
Results: BMPCs were found in elutriation fractions containing
less than 30% T cells and more than 60% monocytes from the
blood of more than 100 normal persons. BMPCs adhered to
plastic and glass and proliferated logarithmically in DMEM–20%
FCS without added growth factors. The initial elutriate had only
small, round, mononuclear cells; upon culture, these were
replaced by fibroblast-like cells and large, round, stromal cells.
The formation of cells with fibroblast-like and stromal
morphology was not affected by eliminating CD34, CD3, or
CD14 cells from the elutriation fraction. Osteogenic
supplements (dexamethasone, ascorbic acid, and b-glycero-
phosphate) added to the culture inhibited fibroblast formation,
and BMPCs assumed the cuboidal shape of osteoblasts. After
5 days in supplemented medium, the elutriated cells displayed
AP and its production was doubled by the addition of BMP2
(1ng) (P<0.04). Two weeks later, 30% of the cells were very
large and reacted with anti-osteocalcin antibody. The same
cultures contained two other types of cell: sudanophlic
adipocytes and multinucleated giant cells, which stain for TRAP
and vitronectin receptors (attributes of osteoclasts). Cultured
BMPCs were immunostained by antibodies to vimentin, type I
collagen, and BMP receptors (heterodimeric structures
expressed on mesenchymal lineage cells). The cultured cells
also stained strongly for the SH-2 (endoglin) antigen, a putative
marker for marrow MSCs. BMPCs express the gene for SDF-1,
a potent stroma-derived CXCa chemokine.
Discussion: In the circulation of normal individuals is a small
population of CD34– mononuclear cells that proliferate rapidly
in culture as an adherent population with a variable
morphology, display cytoskeletal, cytoplasmic, and surface
markers of mesenchymal precursors, and differentiate into
several lineages (fibroblasts, osteoblasts, and adipocytes).
These are all features found in bone-marrow-derived MSCs.
Therefore, autologous blood could provide cells useful for tissue
engineering and gene therapy. In addition, the demonstration of
similar cells in the inflammatory joint fluids and synovium of
patients with rheumatoid arthritis (RA) suggests that these cells
may play a role in the pathogenesis of RA.http://arthritis-research.com/content/2/6/477
embryonic mesenchyme and postnatally on osteoblasts and
chondrocytes [5]. Another antibody, Stro-1 made against
marrow fibroblastic cells, blocks hematopoiesis in vitro by
interfering with the interaction of reconstituted human
hematopoietic stem cells (HSCs) and stromal cells [6].
Attempts to demonstrate MSCs in peripheral blood have
been unrewarding, except for a report by Fernandez et al
[7], who identified cells with the features of MSCs in
growth-factor-mobilized peripheral-blood cells from
breast-cancer patients. Low-density mononuclear cells
grown for 1 week in tissue culture with fetal calf serum
(FCS) become adherent fibroblast-like cells and a few
were large, flat, round cells. Immunohistology and flow
cytometric analysis in a fluorescence-activated cell sorter
(FACS) revealed fibronectin and three types of collagen (I,
III, and VI) in the cytoplasm of the cultured cells. They
expressed adhesion ligands and antigens recognized by
SH-2 and SH-3 monoclonal antibodies. No stromal cells
were demonstrated in normal peripheral-blood cells not
mobilized by granulocyte-macrophage CSF [7]. Bucala et
al [8] separated human blood cells by density centrifuga-
tion, cultured them on a fibronectin matrix, and identified a
population of circulating cells that had fibroblast proper-
ties and a distinctive phenotype (collagen+/vimentin+/
CD34+). This novel circulating cell, termed a fibrocyte, has
both mesenchymal and hematopoietic features.
Now we report for the first time that cells with the morphol-
ogy and phenotype of mesenchymal precursors are nor-
mally present in the circulation. Hereafter these are referred
to as ‘blood-derived mesenchymal precursor cells’
(BMPCs). The observations that support these conclusions
and the significance of the findings are discussed.
Methods
Reagents and laboratory ware
Dexamethasone, ascorbic acid-2 phosphate, b-glycero-
phosphate, bovine serum albumin (BSA), and FCS were
purchased from Sigma Diagnostics (St Louis, MO, USA);
penicillin, streptomycin, DMEM, and RPMI-1640 from
Biowhittaker (Watersville, MD, USA); Lymphoprep™ from
Nycomed, Oslo, Norway.
Monoclonal antibodies were purchased from commercial
vendors unless otherwise stated: CD3, IgG1; CD68,
IgG1; CD34, IgG1; CD45, IgG1, D105, IgG1; and IgG2a
controls (Dako Corporation, Carpinteria, CA, USA); anti-
HLA-DR, IgG2a; CD14, IgG2b; CD34, IgG1 (Becton
Dickinson, San Jose, CA, USA); anti-vimentin, IgG1;
IgG2b control (Serotec, Kidlington, Oxfordshire, UK); anti-
VCAM-1, IgG1; anti-avb 3 (vitronectin receptor), IgG1
(Pharmingen, San Diego, CA, USA); anti-collagen-type-1,
IgG1 (Sigma Diagnostics); anti-osteocalcin, IgG1 (ABOC-
5021, Haematologic Technologies, Essex Junction, VT,
USA) anti-IgG1. Stro-1 is a culture supernatant, mono-
clonal IgM, from Developmental Studies Hybridoma Bank,
University of Iowa (Iowa City, IA, USA). Biotinylated mouse
Ig, streptavidin/horseradish peroxidase conjugate, diamino
benzidine, and Vectastain ABC were from Vector
(Burlingame, CA, USA).
Tissue-culture treated glass slides, Petri dishes, and six-
well tissue-culture plates and eight-chamber tissue culture
slides (Falcon) were from Becton Dickinson Labware
(Franklin Lakes, NJ, USA); 12-well sterile glass slides were
from ICN (Costa Mesa, CA, USA).
Elutriation procedure for BMPCs
Anticoagulant-treated, platelet-depleted buffy coat was
obtained in sterile packages from the North London Blood
Transfusion Service. About 50ml of the buffy coat was
diluted 1:4 in RPMI and 25ml was layered over 20ml of
Lymphoprep™ in a 50-ml conical centrifuge tube. The
tubes (approximately eight) were centrifuged at 2000rpm
for 20 min. The supernatant was discarded and leukocyte-
rich interface cells were collected and combined. These
were made up to 20ml in RPMI and layered again over
Lymphoprep™ and centrifuged at 2000rpm for 20 min
more. The buffy coat, now depleted of red blood cells,
was collected from the interface, resuspended in 50ml of
sterile RMPI and 5% heat-inactivated FCS, and intro-
duced into the sample line of the flow system of a
Beckman JE-50 cell elutriator which had been charged
with elutriation buffer. The chamber was centrifuged at
25000rpm at 10°C and the flow rate adjusted to
12ml/min. The eluate fractions were collected in sterile,
conical, 50-ml tubes. After about 150ml had been col-
lected, the flow rate was increased by 1ml/min. Fractions
nos. 1–6 (flow rates of 12–16ml/min) contained most of
the lymphocytes. Monocytes usually made their appear-
ance (as determined by FACS analysis) in fraction 6 or 7.
In fractions 7 and 8, monocytes constituted up to two
thirds of the cells, and BMPCs were concentrated in
these fractions. Elutriation fractions containing more than
50% and less than 75% monocytes were concentrated by
centrifugation at 1200rpm for 5 min, and the cell pellets
were combined, reconstituted in DMEM plus 20% sterile
heat-inactivated FCS (hereafter referred to as complete
medium, unless otherwise stated), counted in a hemocy-
tometer, washed in DMEM medium, repelleted, resus-
pended to 5×106/ml, and dispensed into either plastic
tissue-culture slides or glass chamber slides.
More than 100 consecutive buffy coats from normal indi-
viduals were processed by this method and cultured. In
every case, the appropriate elutriation fractions had cells
with the BMPC morphology.
Cell-proliferation assay
The BMPC-rich elutriation fractions were plated at 5×105
in 500ml of complete medium in polystyrene chambers ontreated glass tissue-culture slides (Falcon). At various
times, cultures were rinsed twice with Tyrode’s balanced
salt solution, fixed with 1% glutaraldehyde (v/v) in Tyrode’s
for 15 min, rinsed twice with deionized water, and air-
dried. Cultures were then stained with 0.1% crystal violet
(w/v) in deionized water for 30 min and washed 3 times
with deionized water; the crystal-violet dye was extracted
by rocking the cultures gently in 1% Triton X-100 for 4h at
room temperature and read at 595nm on a microplate
reader (BioRad, Hercules, CA, USA). Absorbance values
(optical densities; ODs) were converted into absolute cell
numbers on the basis of established standard curves [9].
Immunohistochemistry
BMPC-rich elutriation fractions (500ml, containing
5×10 6 cells per ml) or other sources of BMPCs were
placed into the wells of sterile, 12-well multitest slides
(ICN) in complete medium and left to adhere at 37°C for
4h. The slides were then placed into 100 × 20 mm Petri
dishes containing 5–7ml DMEM–20% FCS. The nonad-
herent cells floated off, while mesenchymal cells adhered,
spread, and grew. Their daily progress was assessed by
phase-contrast microscopy. The medium was changed
every 3 to 5 days and the cells were studied after 5–7
days. The growing, adherent cells were rinsed in phos-
phate-buffered saline (PBS), fixed in ice-cold 4%
paraformaldehyde for 20 min, and then washed in PBS.
All further incubations and washes were carried out using
PBS. Endogenous peroxidase activity was blocked with
0.1mol sodium azide containing 1% hydrogen peroxide,
and the specimens were incubated with 10% normal
goat serum, 2% normal rat serum, and 1% bovine serum
albumin for 30 min at room temperature to eliminate non-
specific binding. Specimens were then incubated with
primary antibodies at 4°C overnight and were then incu-
bated with a biotinylated secondary antibody (Vector).
The antibody–biotin conjugates were detected with an
avidin–biotin–peroxidase complex (Vector), applied for
30 min at room temperature. A color reaction was devel-
oped with 3-amino-9-ethylcarbazole and specimens were
lightly counterstained with Mayer’s hematoxylin.
Controls included normal rabbit or mouse IgG, 1% BSA in
PBS, or, in the case of BMPR antibodies, preabsorbed
with the respective peptide used for immunization.
Quantification of BMPCs by immunohistochemistry
BMPC-rich elutriation fractions (5×105 cells in 500ml of
complete medium) were placed into the chambers of
sterile, eight-chamber, treated glass tissue-culture slides.
Two to 4h later, nonadherent cells were removed. Cul-
tures were fed every 3 days. At regular intervals, the slides
were rinsed in PBS, fixed in ice-cold 4% paraformalde-
hyde for 20 min, washed in PBS, stained with anti-BMPR
antibodies, and visualized by the ABC immunoperoxidase
method described above. The specimens were examined
using an Olympus BH-2 microscope and analyzed by
computer image analysis (AnalySIS, Soft Imaging System
GmbH, Münster, Germany). Six digital images (400×) per
specimen were recorded and quantitative analysis was
performed according to the color cell separation. Images
chosen at random were analyzed and the data are pre-
sented as the mean of the total number of cells per six
images examined at 400×. Slender cells with a small, cen-
trally localized nucleus were scored as fibroblast-like.
Large, round cells and intermediate-sized cells with more
cytoplasm and a large, round nucleus were scored as
large cells.
Anti-BMPR antibodies
Rabbit polyclonal antibodies to BMPRs were provided by
K Funa (Göteborg University, Gothenburg, Sweden). Poly-
clonal rabbit antisera were prepared using synthetic pep-
tides corresponding to the intracellular transmembrane
portions of the types IA, IB, and II BMPRs [10]. The antis-
era were affinity-purified and tested for specificity by
immunoprecipitation of cross-linked complexes of cultured
cells transfected with receptor complementary deoxyri-
bonucleic acids (cDNAs) [11].
Magnetic antibody-coated-bead separation (MACS) was
performed in accordance with the manufacturer’s recom-
mendations (Miltenyi Biotec, Inc., Auburn, CA, USA). Elu-
triation fractions with 50–75% monocytes were
centrifuged at 900 × g, washed with MACS buffer (PBS
pH 7.2, + 0.5% SSA + 2mmol EDTA) and counted in a
hemocytometer. The cell pellet was resuspended in 80ml
MACS buffer per 107 total cells, and 20ml of MACS anti-
body-coated beads was added to the cells, mixed, and
incubated for 15 min at 6–12°C. The cells were washed
with a 20-fold volume of MACS buffer, spun, and resus-
pended in 500ml buffer. The cell suspension was applied
to a positive selection column washed previously with 1ml
MACS buffer and placed in a magnetic separator and the
cells were eluted. The column was rinsed four times with
500ml buffer and the cells that passed through were com-
bined as the antigen-free fraction. The column was
removed from the magnetic separator, 1ml of buffer was
added to the column, and the positive cells were flushed
out with a syringe plunger. This was repeated with another
1ml of buffer. The elutriated cells were combined as the
antigen-containing fraction.
Alkaline phosphatase activity of circulating BMPCs
BMPC-rich elutriation fractions were prepared from four
individual blood packs as described and plated into four-
well  chamber slides (Lab-Tek) at 5×106 cells per ml in
DMEM–10% FCS. After 24h at 37°C, the nonadherent
cells were removed and new medium was added contain-
ing BMP2 (a gift from the Genetics Institute, Cambridge,
MA, USA) at concentrations of 0, 1, 10, or 100ng/ml. The
cells were incubated at 37°C in 5% CO2 and the medium
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10, and 15 days and stored at –20°C for later analysis. AP
activity in the supernatants was estimated using a p-nitro-
phenol colorimetric assay. Cell supernatants were
assayed for AP activity in 50mmol glycine, 0.05% Triton
X-100, 4mmol MgCl2, and 5mmol p-nitrophenol phos-
phate, pH 10.3, for 15 min at 37°C (Sigma Diagnostics,
St Louis, MO). OD was measured at 405nm and com-
pared with that of standards.
Stromal-cell-derived factor (SDF)-1 RT-PCR
RNA was isolated from BMPCs cultured for 7–12 days
using the Qiagen RN Easy kit (Qiagen, Santa Clarita, CA,
USA). RNA was then used for the first-strand cDNA syn-
thesis in the SuperScript Preamplification System
(GIBCO, BRL, Rockville, MD, USA) in accordance with
the manufacturer’s instructions. SDF-1 specific primers:
5¢-GAGGATCCGACGGGAAGCCC-GTCAGC; 3¢-GAA-
TTCACATCTTGAACCTCTTG. The annealing tempera-
ture was 58°C and the reaction proceeded for 35 cycles.
The glyceraldehyde-3-phosphate dehydrogenase (GA3PD)
gene was included as a reverse transcriptase polymerase
chain reaction (RT-PCR) control and performed under
similar conditions to normalize for the amount of RNA.
Reaction products were analyzed in 2% agarose gel con-
taining 0.25mg/ml ethidium bromide.
Data analysis and statistics
Results are shown as the standard error about the mean
(SEM) of at least three experiments each. For statistical
comparison between groups, the Student paired t test or
Bonferroni  t test was used. Analyses were performed
using the Biostatistics software developed by Stanton A
Glantz (UC San Francisco, CA, USA). Flow cytometry
data were analyzed using the FlowJo software.
Results
BMPCs selected by elutriation of normal human blood
When the elutriated cells from the fractions between the
smaller T cells and the larger, more granular monocytes
were cultured in complete medium without any other sup-
plements, they appeared small and round on examination
by phase-contrast microscopy. Some of them were nonad-
herent (presumably T lymphocytes) and were removed
with the initial feeding of the culture. After 72h, elongated
cells with a fibroblast-like morphology and large cells with
a clear, thin, adherent cytoplasm around a central nucleus
made their appearance. Over the ensuing 7–14 days, they
became the predominant cells in the culture (Fig. 1a). At
higher magnification they could often be seen to have a
splayed, spreading cap at the end and a small, central
nucleus. Another cell population, consisting of larger and
wider cells, with more cytoplasm and a larger nucleus,
was intermediate in morphology between the large, round
cells and the thinner, fibroblast-like cells (Fig. 1b). Culture
conditions modified the morphology of the elutriated cells.
Adding dexamethasone (100nmol) at the initiation of the
culture significantly reduced (by 60%±10%) the total
number of cells at the 7th to 10th days and decreased the
formation of fibroblast-like cells (data not shown). Cultures
supplemented with a mixture of 100nmol dexamethasone,
0.05mmol ascorbic acid-2-phosphate, and 10mmol
b-glycerophosphate (conditions that favor the develop-
ment of osteoblasts) developed only round or cuboidal
cells, and not fibroblast-like ones (Fig. 1c). Dexametha-
sone alone added at days 6 to 8 reduced fibroblast
numbers, but not the total cell numbers (data not shown).
BMPC-rich elutriation fractions observed in time-lapse
cinematography
Clusters of small round cells formed within 24h. Cell
processes occasionally extended from them, but these
retracted minutes later (Fig. 2a). Individual cells were
motile and often left the field, but the clusters remained
intact. After 72h, a few cells with a fibroblast-like morphol-
ogy could be seen beneath and at the edges of the clus-
ters. The fibroblast-like cells were much larger than the
initial cells and quite mobile, extending and retracting
usually about a broad, fixed cup, or pseudopod. By 6 days,
a significant portion of the cells retained their elongated
form and looked like the cells in Fig. 2b. Large, round cells
were also present. Thus, it appears that BMPCs in the cir-
culation were present as small, round mononuclear cells
and their subsequent morphology and function were dic-
tated by culture conditions.
http://arthritis-research.com/content/2/6/477
Figure 1
Appearance of cells isolated from a BMPC-rich elutriation fraction of
healthy human blood and cultured in DMEM–20% FCS for 8 days
(a, b). At this time, the predominant cells consist of both fibroblast-like
cells with a central nucleus, filmy cytoplasm, and adherent pseudopods,
and large, round cells with a thin, adherent cytoplasm and a round,
central nucleus. Hematoxylin staining. (a) ×200; (b) ×400. (c) The
appearance of cells isolated from the same BMPC-rich elutriation
fraction of healthy human blood and cultured in DMEM–20% FCS
supplemented at the initiation of culture with dexamethasone (10–7mol),
ascorbic-acid-2-phosphate (0.05mmol), and b-glycerophosphate
(10mmol) for 8 days. At this time, all the cells have a round or cuboidal
morphology with a centrally placed nucleus. ×200. Compare with the
nonsupplemented cultures in (a).Cell numbers in the BMPC-rich elutriation fraction from
500ml of normal human blood
Elutriation fractions were selected for quantification of
BMPCs based on cell size (intermediate between lympho-
cytes and monocytes) and granularity (FACS). This popu-
lation comprised less than 35% lymphocytes and more
than 50% monocytes. Nineteen consecutive samples had
an average total cell number of 2.14±0.22 (SEM)×107,
of which 64.4%±1.5% (SEM) were monocytes. A sub-
population, estimated as 0.3–0.7% of the starting elutria-
tion fractions, was judged to consist of BMPCs on the
basis of their morphology, their strong adherence to
plastic or glass, and their ability to proliferate in
DMEM–20% FCS without added growth factors (ie <1%
of the starting 2×107 elutriated cells represents 1000 to
10000 BMPCs). Therefore, it is likely that 500ml of
normal blood will have several thousand BMPCs.
Cultures were established with 5×105 cells from the elu-
triation fractions and proliferation was measured on days
3, 10, and 17. Nonadherent cells were removed in the first
24h and the cultures were fed twice weekly. The cells
grew logarithmically, with an approximate doubling time of
2.5 days. By day 17, the initial 5×105 cells multiplied to
6.7×10 7 (Table 1). The culture conditions are not con-
ducive to growth of lymphocytes or monocytes; therefore,
by week 3, most of the proliferating population in cultures
were mesenchymal cells (<20% CD14-staining cells; data
not shown).
Cells from a BMPC-rich elutriation fraction of healthy
human blood were cultured in DMEM–20% FCS. At days
3, 5, 8, and 11 the cultured cells were fixed, stained with
anti-BMPR antibodies, and quantified with an autoanalyzer
(described in Methods). The results are presented in
Fig. 3 as the means of the total number of cells in six indi-
vidual images. Big cells plus fibroblast-like cells consti-
tuted 37% to 59% of the total. Cells with a fibroblast-like
morphology varied from 21% to 34% of the BMPCs. The
1:2 ratio of fibroblast-like to big cells remained relatively
stable over 11 days of culture, even as the total cell
numbers increased (see Table 1).
Immunohistology of BMPCs
Elutriated cells were grown on sterile 12-well glass slides
(ICN) in DMEM–20% FCS and 6 to 12 days later the cells
were fixed, stained, and examined by immunohistology
(Table 2). The large cells and the fibroblast-like cells
stained with antibodies to both vimentin and collagen
type I. They were also identified by antibodies to one or
the other chain (type IA and type II) of the BMPR (Fig. 4a),
but did not react with an anti-type-IB-receptor-chain anti-
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Figure 2
Time-lapse video cinematography of a BMPC-rich elutriation fraction
cultured in DMEM–20% FCS observed by phase-contrast microscopy.
At day 2 (a), there are small, round cells in clusters and a few cells
with pseudopods. By day 6 (b), there are many large, fibroblast-like
cells and large, round, stromal cells arising from a cluster of small,
round cells.
Table 1
Proliferation of BMPCs
Day Observations OD* No. of cells
0 10 0.098±0.02 0.5×106
3 6 0.111±0.28 1.2×106
10 3 0.282±0.40 7.5×106
17 6 0.505±0.51 6.7×107
OD = optical density; see Methods.
Figure 3
BMPC-rich elutriation fraction from healthy human blood cultured in
DMEM–20% FCS. Cells were fixed, stained with anti-BMPR 1A
antibody (see Methods), and analyzed on days 3, 5, 8, and 11. BMPCs
were determined by morphology (fibroblast-like [hatched bars] or big
cells [filled bars]) and immunoperoxidase staining. Results are
presented as the means of total number of cells in six individual
images. ×400. Computer image analysis (AnalySIS).body. Monoclonal Stro-1 antibody stained most of the
large BMPCs and a few of the fibroblast-like cells, while
anti-CD105 reacted with both populations (Fig. 4b).
BMPCs stained strongly with anti-CD44 antibody. Con-
ventional T-cell (CD3), monocyte (CD14, CD68), and
B-cell (CD20) antibodies stained neither of the two BMPC
populations, nor did they react to anti-LCA (CD45), anti-
VCAM (CD106), or MHC-Class II (anti-DR).
Cell separation by magnetic beads to analyze the
contribution of CD34+ progenitors, monocytes, and
T lymphocytes to BMPC formation
BMPC-rich elutriation fractions were incubated with mag-
netic beads coated with specific antibodies and subse-
quently separated into adherent (antigen-enriched) and
nonadherent (antigen-depleted) populations. These were
cultured in complete medium in six-well plates and
observed daily by phase-contrast microscopy. The CD34-
depleted fraction always developed many examples of both
types of mesenchymal cells (seven experiments). The
fibroblast-like cells appeared in the CD34-depleted cul-
tures at the same time as in untreated controls (usually day
3 or 4). There were not enough CD34+ cells to establish
cultures. A representative experiment is shown in Table 3.
In two additional experiments, the cells from the elutriation
fraction were exposed to CD34 beads and the negative
fraction was separated again on fresh CD34 beads. There
was no reduction in the time of appearance or number of
fibroblast-like cells. Thus, although BMPCs were present in
an elutriation fraction that contained CD34+ cells, the two
types of cell could be distinguished from one another.
Findings with anti-CD14 beads were somewhat different.
Both CD14+ and CD14– eluates developed fibroblast-like
cells in culture, but the numbers were less than in unfrac-
tionated controls. In four of five experiments, the fibroblast-
like cells in the CD14+ fraction appeared sooner and in
greater numbers than the CD14– fraction. In all instances,
however, each fraction contained both large, round cells
and fibroblast-like cells and their numbers become more
equal with time (usually by day 13). A representative
experiment is shown in Table 3. When the CD14+ and
CD14– populations were combined, the number of fibrob-
last-like cells and their time of appearance was the same
as in unfractionated controls.
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Table 2
Antibody profile of BMPCs (at days 7–10)
Antibody Large cells Fibroblastoid cells
Vimentin + +
Collagen type I + +
BMPR IA + +
IB 0 0
II + +
STRO-1 + 0
CD3, CD14, CD20 0 0
CD34, CD45, Class II 0 0
Figure 4
BMPC-rich elutriation fraction cultured on a sterile glass slide in DMEM–20% FCS and allowed to proliferate. (a) On day 7, the slide was washed
and the cells were fixed and stained with anti-BMPR Type 1A antibody. In the background are many unstained, small, mononuclear cells. Two types
of cell are stained: one looks like a fibroblast, and the other is a large, round cell with an adherent cytoplasm. (b) A similar culture on day 12,
stained with anti-endoglin (CD105) antibody. The cytoplasm of almost all the large mesenchymal cells shows stippled staining with perinuclear
accentuation. T-cell depletion had no effect on the number, morphology, or
time of appearance of mesenchymal cells (data not shown).
Pluripotent BMPC-fibroblast, osteoblast, and adipocyte
formation
BMPC-rich elutriation fractions cultured in complete
medium supported growth of fibroblasts (spindle-shaped
cells stained by antibodies to vitronectin and type I colla-
gen). When the same elutriated cells were supplemented
with dexamethasone, ascorbic acid, and b-glycerophos-
phate their morphology altered, and they became uniform,
polygonal cells reminiscent of osteoblasts (Fig. 1c). By 10
days, many of the cells stained for AP (not shown). Over
the next 1 to 2 weeks, a subpopulation (approximately
30%) of large cells (which were 3- to 6-fold bigger than
monocytes) developed. They accumulated an ill-defined
pericellular matrix and the osteoblast-specific protein
osteocalcin (Fig. 5a and b). In the same supplemented cul-
tures were sudanophilic adipocytes (Fig. 5a). Another large
cell present after 1 week in the supplemented cultures had
multiple nuclei (Fig. 6a) and stained for tartrate-resistant
acid phosphatase (TRAP) and the vitronectin receptor
(Fig. 6b), which are features of osteoclasts (OCs).
OCs developed in the supplemented BMPC cultures
because both monocytes and stem cells (and/or pre-
osteoblasts ) were present together in the elutriated cells.
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Figure 5
BMPC-rich elutriation fraction cultured in DMEM–20% FCS
supplemented with dexamethasone, ascorbic acid, and
b-glycerophosphate (as described in Fig. 1). After 20 days, about one-
third of the cells are very large. Their cytoplasm stains with an anti-
calcitonin antibody. Immunoperoxidase staining is also observed in the
matrix formed around some of the largest cells. In the same
supplemented cultures are large cells containing neutral lipid (Sudan
IV; red stain). (a) Shows both anti-calcitonin-stained cells (arrows) and
sudanophilic cells (arrowheads) in the same supplemented cultures
(×250) and (b) is at higher magnification (×400) showing a cell and its
surrounding matrix stained with an anticalcitonin antibody (arrow).
Table 3
Outcome of separation of BMPC-rich elutriation fraction using magnetic beads coated with specific antibodies
Starting fraction Post separation
Cells (×106) Monocytes (%) T cells (%) CD antibody coating beads Cells (×106) Fibroblasts/HPFs*
8.7 59 30 34(-) 6.5 ++++
10.5 70 24 14(-) 2.8 +
14(+) 4.8 +
14(+/-) 2.1 +++
*Mean of 6–10 fields. + = up to 5; ++ = 5–10; +++ = 10–15; ++++ = 15–20.
Figure 6
BMPC-rich elutriation fraction cultured in DMEM–20% FCS
supplemented with dexamethasone, ascorbic acid, and
b-glycerophosphate (as described in Fig. 1) and examined daily
thereafter. (a) By day 7 there are many large, multinucleated cells
(phase-contrast microscopy). (b) These cells stain with an anti-
vitronectin receptor antibody (×250).Alkaline phosphatase production
BMPC-rich elutriation fractions from four separate blood
packs were cultured in complete medium with varying
concentrations of BMP2 for 5 days and AP in the super-
natants was measured (Fig. 7). The lowest concentration
of BMP2 (1ng/ml) caused a significant increase in AP
activity (P=0.004). This represents an increased AP pro-
duction per cell, because BMP2 had no effect on BMPC
proliferation over 5 days (data not shown).
Stromal-cell-derived factor 1
SDF-1 is a potent CXCa chemokine produced by bone-
marrow spindle-shaped stromal cells and other cells of
mesenchymal origin, but not blood leukocytes [12,13].
RT-PCR analysis for SDF-1 mRNA expression in two
cDNA samples of cultured BMPCs (lanes 2 and 3) and in
a cDNA from RA synoviocytes (lane 4) are shown in Fig. 8.
Each sample displayed an amplification of a PCR frag-
ment of the expected size for SDF-1 (296bp) and was
similar to the positive control (lane 5), a sequenced
plasmid containing human SDF-1b cDNA.
Discussion
The abilities to self-replicate and to give rise to daughter
cells that undergo an irreversible terminal differentiation
are features of stem cells [14,15]. The best-characterized
are HSCs and their progeny. Friedenstein et al proposed
a similar scheme for mesenchymal cells and showed that
bone marrow contained primitive cells that could generate
progenitors committed to one or another mesenchymal
line [2]. Such cells are called MSCs [1]. Conditions that
direct marrow MSCs along myogenic [16], adipogenic
[17,18], osteogenic [18–20], chondrogenic [19,21], and
stromal pathways [22] have been defined. For instance,
exposure of fibroblast-like marrow MSCs in vitro to
optimal concentrations of dexamethasone, ascorbic acid
and b-glycerophosphate induces a cuboidal morphology,
upregulates AP and osteocalcin expression, and a mineral-
ized (hydroxyapatite) matrix [20].
Lineage differentiation signals can be subtle. Dexametha-
sone at 10–9mol/l supports adipocyte differentiation,
whereas osteogenesis is favored at 10–7mol/l [19].
Human marrow MSCs obtained by Ficoll density gradient
fractionation (1.078g/ml) and cultured in 25% serum (half
horse and half fetal calf) supplemented with hydrocorti-
sone (1mmol) gives rise to a heterogeneous population, in
which fibroblast-like cells do not predominate [22]. Sepa-
ration of the same population of marrow MSCs on a
Percoll density gradient (1.090g/ml) and culture in care-
fully selected 10% FCS resulted in a homogeneous popu-
lation of spindle-shaped fibroblast cells. The
higher-density Ficoll may isolate cells that sediment
through the Percoll solution used for the marrow MSC iso-
lation. Elutriation, as used in this investigation, probably
selects a somewhat different population.
The CD34 status of mesenchymal cells is disputed [7,8]. A
minority of adult marrow cells express CD34. The antigen
is present on pluripotent HSCs, and all unipotent myeloid
and erythroid-colony-forming cells [23], but CD34 is also
recognized on vascular endothelial cells, basement-
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Figure 7
BMPC-rich elutriation fractions (n=4) cultured in DMEM–20% FCS
with varying concentrations of BMP2 for 5 days. Supernatants were
collected and analyzed for alkaline phosphatase activity (AP; the
release of pNP is a measure of AP activity). The lowest concentration
of BMP2 (1ng/ml) caused a significant increase in AP activity.
**P >0.004.
Figure 8
RT-PCR analysis for expression of mRNA for (a) the chemokine SDF-1
and (b) the housekeeping gene GA3PD in cultured BMPCs (GA42,
GA43), and a rheumatoid arthritis synovial fibroblast line (RA505
passage 4). Note the similar RT-PCR fragment size in the samples to
that in an SDF-1 plasmid (lane 5) included as a positive control.
Conditions for RT-PCR and the primers used are described in the
methods section.membrane structures, and dendritic and perifollicular cells
in human skin [24,25]. Simmons and Torok-Storb sepa-
rated human marrow cells on the basis of their CD34
expression [26]. More than 95% of the detectable colony
forming unit fibroblasts were recovered in the adherent
CD34+ population, but their CD34 density was much less
than on CD34high HSCs. Furthermore, only 5% of the
CD34+ marrow cells reacted with the monoclonal antibody
Stro-1, which identifies marrow MSCs [6]. All these studies
were done on marrow MSCs before culture, because after
culture in vitro, the same stromal cells no longer react with
anti-CD34 antibodies [26]. Likewise, although CD34+ cells
are identified in tissue sections of human umbilical vein
endothelial cells, they are not found in vitro [27]. These and
other reports suggest the CD34 glycoprotein is either
down-regulated or modified in vitro to a form that is not
reactive with the usual anti-CD34 antibodies [23]. There-
fore, the failure of Fernandez et al to demonstrate CD34 on
circulating stromal cells mobilized by growth factors was
probably because the cells had been in culture for 10 days
[7]. Similarly, the inability of Majumdar et al to demonstrate
CD34 staining was on first-passage marrow MSCs [22]. In
vitro culture conditions, however, cannot explain our failure
to eliminate BMPCs in fresh elutriation fractions with anti-
CD34-coated magnetic beads, a technique widely used to
harvest CD34+ HSCs from growth-factor-mobilized human
blood. The absorptions were performed on fresh BMPC-
rich elutriation fractions. Therefore, BMPCs either lack
CD34 or have only a very low density of this glycoprotein.
The CD34+ cells called fibrocytes, which are present in
monocyte fractions of human blood and develop a fibrob-
last morphology when grown on fibronectin, have features
identical to those of circulating vascular endothelial cell
progenitors [28] and are probably not BMPCs.
Bone morphogenetic proteins (BMPs) were originally iden-
tified as proteins that induced bone formation at extraskele-
tal sites [29]. Currently, there are 20 or more known BMPs,
all members of a larger TGF-b superfamily. BMPs are
involved in morphogenesis and embryogenesis, influencing
bone, cartilage, and skeletal formation [29–32]. Much of
this information comes from animal cells and embryos, but
the addition of BMP2 to cultured postnatal human bone
marrow ‘preosteoblastic’ cells in the presence of b-glyc-
erophosphate and ascorbic acid increases the gene
message and protein production of AP, osteopontin, bone
sialoprotein, osteocalcin, and a-1 collagen [33]. BMPCs
develop into osteocalcin-producing cells (Fig. 5a) and
make increased amounts of AP in response to BMP2
(Fig. 7). This cannot be explained by proliferation, because
BMP2 reduces the number of marrow MSCs in either
serum or serum-free conditions [33].
BMPRs belong to the TGF-b receptor family of
serine/threonine kinases [34]. Both type I and type II
BMPRs bind their respective ligands, but heterodimeriza-
tion is required for a signal to be transduced [34,35]. For
instance, coexpression of type II BMPR with either IA or IB
BMPR increases ligand-binding affinity and dramatically
enhances biologic activity [11]. Human marrow MSCs
express BMP2/4 type I and II receptors as shown in
studies employing BMP2 as ligand in the presence or
absence of a 100-fold excess of a competitor [33]. BMP
structure is conserved across species, and antibodies to
type I and type II receptors react equally well with murine
and human mesenchymal cells, but not with hematopoietic
cells [34]. This is consistent with our findings that poly-
clonal antibody to BMPRs can be used to identify BMPCs
and constitutes strong evidence that the circulating cells
described in this report are mesenchymal precursors.
BMPCs stain with the Stro-1 monoclonal antibody made
against human bone-marrow stromal cells [6]. Stro-1+
cells cultured in an osteogenic medium exhibit three
markers of differentiated bone: AP; 1,25-dihydroxy-
vitamin-D3-dependent induction of osteocalcin; and a min-
eralized matrix (hydroxyapatite) [36,37]. Stro-1 is
expressed by BMPCs, but the antibody also stains peri-
cytes, cells that surround small-vessel endothelium. Peri-
cytes, which are of mesodermal origin, can also
differentiate into a variety of cell types, including
osteoblasts and adipocytes (reviewed in [38]). The reac-
tivity of pericytes with BMPR antibodies is not known, but
we have used BMPR antibodies to analyze mesenchymal
cells in synovial tissues. The antibodies identify large cells
in the inflamed joint lining, but they do not stain blood
vessels of either normal or inflamed synovium (Marinova-
Mutafchieva, personal communication).
SH-2, a proprietary antibody developed against isolated
bone marrow MSCs [1,3], was not available when these
studies were performed. When SH-2 was identified as
endoglin (CD105) [4], the cells in a BMPC-enriched elutria-
tion fraction of blood were examined with an anti-CD105
monoclonal antibody. The strong cytoplasmic staining of the
large blood mesenchymal cells (Fig. 4b) is more evidence of
the great similarity of marrow MSCs and circulating BMPCs.
Progenitor and precursor B cells require close contact
with marrow MSCs for growth and maturation. Mouse
marrow MSCs contain the gene for a protein (termed
either stromal-cell-derived factor 1 (SDF-1) or pre-B-cell-
growth-stimulating factor (PBSF) [12,13]. SDF-1 is a
powerful CXC chemokine that recruits circulating lympho-
cytes, monocytes, and CD34+ hematopoietic progenitors,
but not neutrophils [39,40]. PBSF is responsible for con-
verting ‘early’ B cells into immunoglobulin-producing cells
[41]. SDF-1 mRNA is constitutively expressed in many
tissues, unlike other chemokines, which are only induced
[41,42]. SDF-1 is expressed in marrow MSCs, dermal
fibroblasts, and synovial fibroblasts, but not HSCs. The
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in cultured BMPCs (Fig. 8) and as protein in supernatants
from cultured BMPCs (data not presented) is additional
evidence that BMPCs are of mesenchymal lineage.
Human OCs arise from HSCs in close proximity to stromal
cells or from blood monocytes. The OC is a TRAP-posi-
tive, large, multinucleated cell with receptors for calcitonin
and vitronectin (avb3) (Fig. 5a) and the capacity to form
resorption lacunae in bone slices [43]. Osteoblast produc-
tion and OC production are tightly linked and regulated.
Osteoblasts facilitate OC formation by providing physical
support and critical soluble factors [43]. Our observation
of spontaneous formation of cells with the morphology
and phenotype of OCs in monocyte-rich (65%) elutriation
fractions is best explained by the simultaneous presence
of BMPCs in the same fractions.
More than 100 normal individuals had CD34– mononu-
clear cells in a fraction of elutriated blood cells that fulfilled
criteria for mesenchymal precursors or stem cells. They
proliferated rapidly in culture, had an adherent, spread
morphology, displayed cytoskeletal, cytoplasmic, and
surface markers of mesenchymal precursors, and had a
capacity for differentiation into fibroblast, osteoblast, and
adipocyte lineages. Thus, autologous blood could be an
important source of cells for tissue engineering and gene
therapy [44–46.] In addition, the finding of similar cells in
the inflammatory joint fluids and synovial tissues of
patients with RA suggests they may play a role in the
pathogenesis of this disease [47].
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